A new study, entitled “Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis,” conducted at Charité University Hospital, Rheumatology and Clinical Immunology in Berlin, Germany, and published in the American Journal of Respiratory and Critical Care Medicine by first author on the study Dr. Mike…

Systemic Sclerosis (SSc) is a disease that is closely associated with Pulmonary Hypertension. According to the Scleroderma Society, “about 1 in 10 people with systemic sclerosis (systemic scleroderma) can go on to develop pulmonary hypertension,” due to the fact that SSc leads to the thickening of the pulmonary…

A new study published in September’s issue of the American Journal of Respiratory and Critical Care Medicine, entitled, “The Sphingosine Kinase 1 / Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension” reports the discovery of two novel therapeutic targets to treat pulmonary arterial hypertension. Pulmonary arterial hypertension…

The Pulmonary Fibrosis Foundation (PFF) and the U.S. Food And Drug Administration will discuss data from a survey requested for the Patient-Focused Drug Development Meeting For Idiopathic Pulmonary Fibrosis, to be held on the 26th of September on the FDA’s White Oak Campus. According to the information…

The Coalition for Pulmonary Fibrosis (CPF), which has chosen September as National Pulmonary Fibrosis Month, recently announced this year’s activities for increasing advocacy and awareness for the disease. According to the organization, the initiative, now in its 12th year, intends to raise awareness of the disease and…

While a major population of pulmonary hypertension patients are diagnosed with idiopathic or arterial pulmonary hypertension, a population of patients with pulmonary hypertension patients due to sarcoidosis is no less affected by the condition. Estimates from a paper published in Seminars in Respiratory and Critical Care Medicine state that…

A new study, entitled “The Sphingosine Kinase 1 / Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension” conducted at University of Illinois’s College of Medicine, at Chicago, published in the American Journal of Respiratory and Critical Care Medicine, by Dr. Jiwang Chen, research assistant professor of critical care…

A new study published in August’s issue of Cardiovascular Research, entitled “Ranolazine prevents INaL enhancement and blunts myocardial remodeling in a model of pulmonary hypertension” suggests ranolazine (RAN) as a potential therapeutic agent in the treatment of PAH pathology. Pulmonary arterial hypertension (PAH) is a result of…

Pulmonary hypertension is a life-threatening, progressive disease that, to this day, is still incurable. Recently, a team of researchers turned to nature for answers, experimenting with extracting a protective enzyme from plant leaves that may hold the key to making a novel treatment work. Lead author and assistant…

The Maryland chapter of the Pulmonary Hypertension Association (PHA) recently announced that it is hosting a presentation on Emergency Preparedness for Pulmonary Hypertension Patients, via their Facebook page, which is taking place on Tuesday, September 23rd at 10 pm. The event is designed to help educated patients on…

Every Breath Counts: Idiopathic Pulmonary Fibrosis, a documentary to mark Pulmonary Fibrosis Awareness Month, will air on the Discovery Channel on September 13th and 27th at 8:00 am ET/PT. Supported by Boehringer Ingelheim Pharmaceuticals, Inc. and created together with the Pulmonary Fibrosis Foundation and the Coalition for Pulmonary Fibrosis, the…

Pulmonary Arterial Hypertension (PAH) is a life-threatening disease in which endothelial dysfunction, vasoconstriction in small pulmonary arteries, dysregulated proliferation of vascular cells, and dysregulated inflammatory signaling leads to pulmonary arterial obstruction increasing pulmonary vascular resistance and resulting in right ventricular failure. Different types of treatments for PAH exist that can…